Biphasic Effects on Allergen‐Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy
Allergy · 2026-06 · 81 (6) · 2172-2183
DOI: 10.1111/all.70342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, online erschienen am 17.04.2026. Verfasst von Lin Hsin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Antigens, Dermatophagoides, B-Lymphocytes, Dust Mite Allergy, Immunologic Memory. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Background
Type 2 memory B cells (Bmem) are the reservoir of pathogenic IgE in allergies. Allergen immunotherapy (AIT) can change the course of disease, but if it involves reprogramming of allergen‐reactive Bmem remains unknown. Here, we examine how AIT affects allergen‐specific Bmem in house dust mite (HDM) allergic patients.
Methods
HDM allergic patients were longitudinally evaluated over 18 months with or without sublingual HDM‐AIT. Visual analog scores, lung function tests, medication scores, serum IgE, and flowcytometric analysis of Der p 1 and Der p 2‐specific Type 2 Bmem were performed at t = 0, 4, 12, and 18 months.
Results
Patients on HDM‐AIT showed clinical improvement over 18 months with reduced intake of other medications and increases in specific serum IgE, IgG2, and IgG4. Allergen‐specific Bmem and the proportions of Type 2 Bmem therein became more abundant at 4 and 12 months and showed upregulation of CD29 and IgG4. At 18 months, the Type 2 Bmem proportions were reduced.
Conclusion
A biphasic Bmem response with early phenotypic changes followed by loss of the Type 2 state was observed during 18 months of AIT. As durable unresponsiveness takes 18 months of AIT, deletion of Type 2 Bmem is likely an important step in disease attenuation. Interventions that expedite this outcome may be beneficial in driving remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.
- Allergy, Asthma and Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.
- Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
- Immune Therapies Group, Burnet Institute, Melbourne, Victoria, Australia.
- Department of Clinical Pathology, the University of Melbourne, Parkville, Victoria, Australia.
- Innovation & Science Department, Stallergenes Greer, Antony, France.
ORCID-Profile: Lin Hsin, Simone Reinwald, Anouk von Borstel, Pei Mun Aui, P Mark Hogarth, Laurent Mascarell, Mark Hew, Robyn E O'Hehir, Menno C van Zelm
Förderung
- National Health and Medical Research Council
Zitieren
APA
Hsin, L., Reinwald, S., von Borstel, A., Aui, P. M., Deckert, K., Hogarth, P. M., Mascarell, L., Hew, M., O'Hehir, R. E., & van Zelm, M. C. (2026). Biphasic Effects on Allergen‐Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy. Allergy, 81(6), 2172-2183. https://doi.org/10.1111/all.70342
Vancouver
Hsin L, Reinwald S, von Borstel A, Aui PM, Deckert K, Hogarth PM, et al. Biphasic Effects on Allergen‐Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy. Allergy. 2026;81(6):2172-2183. doi:10.1111/all.70342
BibTeX
@article{Hsin2026,
author = {Hsin, Lin and Reinwald, Simone and von Borstel, Anouk and Aui, Pei Mun and Deckert, Kirsten and Hogarth, P Mark and Mascarell, Laurent and Hew, Mark and O'Hehir, Robyn E and van Zelm, Menno C},
title = {Biphasic Effects on Allergen‐Specific Type 2 Memory B Cells Over 18 Months Sublingual Immunotherapy for House Dust Mite Allergy},
journal = {Allergy},
year = {2026},
volume = {81},
number = {6},
pages = {2172--2183},
doi = {10.1111/all.70342}
}
EUVIMED